District Of Columbia 2023-2024 Regular Session

District Of Columbia Council Bill B25-0226

Introduced
3/20/23  
Refer
3/21/23  
Introduced
3/20/23  
Report Pass
10/12/23  
Refer
3/21/23  
Engrossed
11/7/23  
Report Pass
10/12/23  
Enrolled
12/8/23  
Engrossed
11/7/23  
Passed
12/21/23  
Enrolled
12/8/23  
Passed
2/23/24  
Passed
12/21/23  

Caption

Access to Emergency Albuterol and Glucagon Amendment Act of 2023 (now known as "Access to Emergency Medications Amendment Act of 2023")

Impact

The bill significantly alters the framework within which public schools operate with regard to student health management. It places a requirement on public schools to have designated staff members certified in the administration of these medications, increasing preparedness for health emergencies involving students. Additionally, schools will be accountable for maintaining an adequate stock of medications and ensuring timely replacement of expired supplies. This is expected to enhance the level of care available to students in emergency situations.

Summary

Bill B25-0226, known as the 'Access to Emergency Medications Amendment Act of 2023', amends the Student Access to Treatment Act of 2007. Its primary aim is to allow public schools to possess and administer undesignated emergency medications, such as albuterol and glucagon, without needing a specific prescription for each student. This legislation mandates that by February 1, 2024, the Department of Health will establish a plan to facilitate this process and ensure that the emergency medications are available in schools when needed.

Sentiment

The sentiment surrounding B25-0226 appears to be generally positive among its proponents who argue that the bill is a vital step toward ensuring student safety and public health. Supporters emphasize that the ability to promptly administer emergency medications can be life-saving and express approval of increased accessibility to essential health treatments within school settings. However, discussions also reflect concerns regarding potential challenges around implementation and the wellbeing of students who may require these medications in critical situations.

Contention

Notable points of contention in the discourse around this bill include the adequacy of training for staff members designated to administer medications and the timely distribution of supplies by the Department of Health. There is a robust dialogue on ensuring that the protocols for medication administration are comprehensive and handle diverse emergency scenarios effectively. School administrators also express a need for clarity on compliance requirements and the support they can expect from health authorities to meet these new legislative demands.

Companion Bills

No companion bills found.

Previously Filed As

DC SB0146

Glucagon Amendments

DC SB0104

School Medication Amendments

DC HB0333

Medications in Schools Amendments

DC S363

Increasing access to emergency diabetes management medication

DC SB3051

SCH CD-UNDESIGNATED GLUCAGON

DC SB92

Glucagon for Schools Act

DC HB2360

AN ACT Relating to expanding access to albuterol in public and private schools;

DC SB1347

An act to amend Section 49414.7 to of the Education Code, and to add Section 4119.21 to the Business and Professions Code, relating to pupil health.

DC HB600

Authorize emergency use of albuterol in a school setting

DC HB263

AN ACT relating to undesignated glucagon.

Similar Bills

KY HB75

AN ACT relating to undesignated glucagon.

KY HB174

AN ACT relating to undesignated glucagon.

KY HB263

AN ACT relating to undesignated glucagon.

NJ A4548

Concerns administration of ready-to-use undesignated glucagon rescue therapy in public schools.

MA H671

Relative to undesignated glucagon rescue therapies in schools

WV SB92

Glucagon for Schools Act

FL H0597

Diabetes Management in Schools

NJ S3624

Concerns food allergy safety, emergency preparedness, and anaphylaxis response in child care settings.